StimAire, a US-based injectable neuromodulation company developing medical devices for obstructive sleep apnoea (OSA), announced on Monday that it has named Arthur Rascon as its new chief operating officer (COO), effective 22 July 2024.
Rascon has more than two decades of experience in operational leadership and a proven track record of driving innovation and commercialisation in the medical device industry. He has worked as the chief executive officer at Valencia Technologies Corporation. He has worked as senior director of Manufacturing Engineering at Medtronic Diabetes, vice president of Manufacturing and Quality Engineering, and senior director of Product Engineering at Advanced Bionics.
Tarek Makansi PhD, StimAire president and chief technology officer, said, 'We are thrilled to welcome Arthur Rascon to the full-time leadership team. Arthur will move our company and product forward from a demonstrated technology to a certified medical device offering with the goal of improving the lives of those affected by obstructive sleep apnoea.'
Amylyx receives EU Orphan Drug Designation for Wolfram syndrome treatment
KVK Tech registers Lomaira 8mg tablets in Mexico
GSK's Arexvy receives positive CHMP opinion for at-risk adults aged 50-59
M8 Pharmaceuticals signs exclusive licensing and distribution agreement with LG Chem
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
StimAire names new chief operating officer
TME Pharma to monetise clinical asset NOX-E36 for ophthalmology
Genentech reports positive Phase I Results for oral GLP-1 agonist CT-996